Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 6.52% and Operating profit at 11.86% over the last 5 years
2
Flat results in Mar 26
3
With ROE of 14.76%, it has a fair valuation with a 1.94 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,913 Million (Large Cap)
18.00
NA
2.92%
-0.34
14.76%
2.09
Revenue and Profits:
Net Sales:
542 Million
(Quarterly Results - Mar 2026)
Net Profit:
172 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.73%
0%
-2.73%
6 Months
-14.59%
0%
-14.59%
1 Year
-21.77%
0%
-21.77%
2 Years
-1.16%
0%
-1.16%
3 Years
-12.58%
0%
-12.58%
4 Years
-9.14%
0%
-9.14%
5 Years
-34.98%
0%
-34.98%
Anhui Anke Biotechnology (Group) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.52%
EBIT Growth (5y)
11.86%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.64
Tax Ratio
9.53%
Dividend Payout Ratio
56.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
31.52%
ROE (avg)
18.43%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
2.64
EV to EBIT
14.73
EV to EBITDA
13.05
EV to Capital Employed
3.50
EV to Sales
4.26
PEG Ratio
NA
Dividend Yield
2.31%
ROCE (Latest)
23.72%
ROE (Latest)
14.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
541.70
683.90
-20.79%
Operating Profit (PBDIT) excl Other Income
188.30
202.50
-7.01%
Interest
0.10
0.30
-66.67%
Exceptional Items
4.20
0.10
4,100.00%
Consolidate Net Profit
172.20
184.70
-6.77%
Operating Profit Margin (Excl OI)
347.60%
249.30%
9.83%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -20.79% vs 2.01% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -6.77% vs -1.81% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,633.80
2,523.70
4.36%
Operating Profit (PBDIT) excl Other Income
912.20
863.00
5.70%
Interest
3.10
3.50
-11.43%
Exceptional Items
1.90
11.40
-83.33%
Consolidate Net Profit
747.30
715.80
4.40%
Operating Profit Margin (Excl OI)
298.20%
292.70%
0.55%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 4.36% vs -11.48% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 4.40% vs -16.63% in Dec 2024
About Anhui Anke Biotechnology (Group) Co., Ltd. 
Anhui Anke Biotechnology (Group) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






